Risks of nonadherence to hormone therapy in Asian women with breast cancer
- PMID: 26043413
- PMCID: PMC11916748
- DOI: 10.1016/j.kjms.2015.04.002
Risks of nonadherence to hormone therapy in Asian women with breast cancer
Abstract
The aim of this study was to quantify the hormone therapy (HT) nonadherence patterns and to assess the associated risk factors in Asian women with breast cancer. This retrospective cohort study used the Taiwan Health Insurance Research Database from 2003 to 2011. Data from women with newly diagnosed primary breast cancer were identified, and persistence (without HT prescribing gap ≥ 180 days) to HT was defined through records of dispensing prescriptions. Study cohorts were further classified as adjuvant and primary HT groups. Each individual's HT utilization patterns and the medication possession ratio at overall HT course were measured. The odds ratios (ORs) of nonadherence (medication possession ratio, <80%) in adjuvant and primary HT patients were estimated using logistic regressions with adjustment of potential confounding variables. These patients had 15.6% and 23.4% nonadherence rates to HT in adjuvant and primary HT groups, respectively. In the adjuvant HT group, older age groups (≥50 years) and taking aromatase inhibitors were less likely to show nonadherence (p < 0.05). In the primary HT group, women older than 70 years were significantly less likely to exhibit nonadherence (OR = 0.53; 95% confidence interval, 0.28-0.99); however, women with presence of HT-related adverse events had significantly increased risk (OR = 1.44; 95% confidence interval, 1.02-2.03). Young age and experience of musculoskeletal and joint symptoms were identified as risk factors for nonadherence.
Keywords: Adherence; Breast cancer; Drug utilization; Hormone therapy; Nonadherence.
Copyright © 2015. Published by Elsevier Taiwan.
Similar articles
-
Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.JAMA Oncol. 2016 Oct 1;2(10):1326-1332. doi: 10.1001/jamaoncol.2016.1291. JAMA Oncol. 2016. PMID: 27281650
-
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.J Clin Oncol. 2010 Sep 20;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655. Epub 2010 Jun 28. J Clin Oncol. 2010. PMID: 20585090 Free PMC article.
-
Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy.Obstet Gynecol. 2018 Nov;132(5):1137-1142. doi: 10.1097/AOG.0000000000002914. Obstet Gynecol. 2018. PMID: 30303924
-
Adherence to long-term adjuvant hormonal therapy for breast cancer.Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-15. doi: 10.1586/erp.11.80. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098287 Review.
-
Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.Cochrane Database Syst Rev. 2020 Mar 6;3(3):CD013538. doi: 10.1002/14651858.CD013538. Cochrane Database Syst Rev. 2020. PMID: 32141074 Free PMC article.
Cited by
-
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies.Pharmaceuticals (Basel). 2021 Feb 3;14(2):115. doi: 10.3390/ph14020115. Pharmaceuticals (Basel). 2021. PMID: 33546125 Free PMC article.
-
Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.J Breast Cancer. 2023 Aug;26(4):309-333. doi: 10.4048/jbc.2023.26.e22. Epub 2023 May 10. J Breast Cancer. 2023. PMID: 37272247 Free PMC article.
-
Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.PLoS One. 2022 Jan 28;17(1):e0262934. doi: 10.1371/journal.pone.0262934. eCollection 2022. PLoS One. 2022. PMID: 35089956 Free PMC article. Clinical Trial.
-
A Systematic Review of Adherence to Oral Antineoplastic Therapies.Oncologist. 2016 Mar;21(3):354-76. doi: 10.1634/theoncologist.2015-0405. Epub 2016 Feb 26. Oncologist. 2016. PMID: 26921292 Free PMC article.
-
Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.Patient Prefer Adherence. 2017 Feb 23;11:305-322. doi: 10.2147/PPA.S126651. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28260867 Free PMC article. Review.
References
-
- Haynes R.B., Sackett D.L., Taylor D.W., Roberts R.S., Johnson A.L.. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin Pharmacol Ther. 1977; 22: 125–130. - PubMed
-
- Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non‐adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25: 481–496. - PubMed
-
- Liu G., Franssen E., Fitch M.I., Warner E.. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15: 110–115. - PubMed
-
- Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006; 17: 205–210. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous